Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;8(3):246-51.
doi: 10.2174/156720511795563764.

Frontotemporal dementia caused by CHMP2B mutations

Affiliations
Free PMC article
Review

Frontotemporal dementia caused by CHMP2B mutations

A M Isaacs et al. Curr Alzheimer Res. 2011 May.
Free PMC article

Abstract

CHMP2B mutations are a rare cause of autosomal dominant frontotemporal dementia (FTD). The best studied example is frontotemporal dementia linked to chromosome 3 (FTD-3) which occurs in a large Danish family, with a further CHMP2B mutation identified in an unrelated Belgian familial FTD patient. These mutations lead to C-terminal truncations of the CHMP2B protein and we will review recent advances in our understanding of the molecular effects of these mutant truncated proteins on vesicular fusion events within the endosome-lysosome and autophagy degradation pathways. We will also review the clinical features of FTD caused by CHMP2B truncation mutations as well as new brain imaging and neuropathological findings. Finally, we collate the current data on CHMP2B missense mutations, which have been reported in FTD and motor neuron disease.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Multiple alignment of CHMP2B proteins. Wildtype CHMP2B and C-terminal truncations CHMP2BIntron5, CHMP2BDelta10 and CHMP2BQ165X were aligned with CHMP2B homologues from other species. The novel C-termini of CHMP2BIntron5 and CHMP2BDelta10 are highlighted in yellow. CHMP2B missense mutations identified in FTD-MND spectrum disorders are arrowed.
Fig. (2)
Fig. (2)
Representative brain scans in FTD-3 patients. Upper row: structural scans in FTD-3 with MRI for patients A and B, and a CT-scan for patient C. Lower row shows cerebral blood flow as measured by with H215O -PET scanning for the same 3 patients.

References

    1. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51:1546–1554. - PubMed
    1. McKhann GM, Albert MS, Grossman M, Miller B, Dickson D, Trojanowski JQ. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol. 2001;58:1803–1809. - PubMed
    1. Lillo P, Hodges JR. Frontotemporal dementia and motor neurone disease: overlapping clinic-pathological disorders. J Clin Neurosci. 2009;16:1131–1135. - PubMed
    1. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol (Berl) 2007;114:5–22. - PMC - PubMed
    1. Josephs KA, Petersen RC, Knopman DS, Boeve BF, Whitwell JL, Duffy JR, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology. 2006;66:41–48. - PubMed

Publication types

MeSH terms

Substances